Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings estimates for Xenon Pharmaceuticals in a research note issued on Monday, March 17th. William Blair analyst M. Minter anticipates that the biopharmaceutical company will post earnings of ($1.01) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals' Q2 2026 earnings at ($1.03) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.12) EPS and FY2026 earnings at ($4.21) EPS.
Several other research analysts have also commented on XENE. HC Wainwright reissued a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price objective on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $57.38.
Check Out Our Latest Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Price Performance
NASDAQ XENE traded up $0.49 during trading on Wednesday, reaching $35.34. The company's stock had a trading volume of 475,319 shares, compared to its average volume of 378,967. The firm has a fifty day moving average of $38.14 and a 200 day moving average of $39.88. Xenon Pharmaceuticals has a one year low of $33.27 and a one year high of $46.00. The stock has a market capitalization of $2.71 billion, a PE ratio of -12.53 and a beta of 1.26.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05.
Insiders Place Their Bets
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,258,340.40. The trade was a 41.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.52% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in XENE. GF Fund Management CO. LTD. purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $63,000. Quarry LP purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $78,000. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 140.3% in the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after purchasing an additional 1,414 shares during the last quarter. Avior Wealth Management LLC purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $101,000. Finally, KBC Group NV raised its position in Xenon Pharmaceuticals by 39.8% during the 4th quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 780 shares during the last quarter. Institutional investors own 95.45% of the company's stock.
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
